Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lixudebart by Alentis Therapeutics for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase II for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)....
Lixudebart by Alentis Therapeutics for Kidney Fibrosis: Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase II for Kidney Fibrosis. According to GlobalData, Phase...
Lixudebart by Alentis Therapeutics for Liver Fibrosis: Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase I for Liver Fibrosis. According to GlobalData, Phase...
Lixudebart by Alentis Therapeutics for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Lixudebart is under clinical development by Alentis Therapeutics and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData,...